At the European Society for Medical Oncology 2024, the interim report of the clinical trial for peritoneal dissemination (gastric/pancreatic cancer) will be presented

Fukuoka, JAPAN – Dr. Eiji OKI, MD PhD, the Department of Surgery and Science at Kyushu University Hospital, will present the interim report of the clinical trial for peritoneal dissemination (gastric/pancreatic cancer) at the European Society for Medical Oncology 2024 (ESMO 2024).

Presentation Information:

Title: Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presentation Number: 1470TiP
Scheduled for: September 16, 2024 (Monday), Fira Barcelona Gran Via, Barcelona, Spain

About the Study:

This clinical study aims to gauge both the safety and clinical efficacy of GAIA-102. The study has been registered under ClinicalTrials.gov ID: NCT05438459.
Dr. Eiji OKI is the principal investigator of the study.

Funding & Support:

This crucial study has received financial backing from the Japan Agency for Medical Research and Development (AMED). Additionally, GAIA BioMedicine Inc. has generously provided the test drug.

About GAIA BioMedicine:

GAIA BioMedicine, Inc., founded in 2015 by Prof. Yoshikazu YONEMITSU, MD PhD, as a spin-off venture of Kyushu University, is a clinical-stage and technology-driven biopharmaceutical company specializing in cell therapies for cancer using GAIA-102, NK-cell like cells.

Share on